Brief: Cidara Therapeutics Announces First Participants Dosed In Phase 3 Anchor Trial Evaluating Cd388
25/09/2025 22:57
Sept 25 (Reuters) - Cidara Therapeutics Inc CDTX.O: CIDARA THERAPEUTICS ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 3 ANCHOR TRIAL EVALUATING CD388 FOR THE PREVENTION OF SEASONAL INFLUENZA IN HIGH-RISK POPULATIONS Source text: ID:nGNX94z7g3 Further company coverage: CDTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cidara Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merck Seeks Up To $8 Billion In Us Bond Sale Tied To Cidara Deal - Bloomberg News
Merck rises after Wells Fargo upgrades stock to 'overweight'
Factbox: Major deals involving U.S. drugmakers and biotechs over the past decade